Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$17.8M Buy
81,900
+45,800
+127% +$10.2M 0.04% 378
2025
Q4
$8.25M Sell
36,100
-24,700
-41% -$5.63M 0.03% 538
2025
Q3
$14.1M Buy
60,800
+33,900
+126% +$6.9M 0.05% 278
2025
Q2
$4.99M Buy
26,900
+19,000
+241% +$3.53M 0.02% 537
2025
Q1
$1.66M Sell
7,900
-3,800
-32% -$739K 0.01% 896
2024
Q4
$2.08M Buy
+11,700
New +$2.15M 0.01% 724
2021
Q1
Sell
-24,000
Closed -$2.57M 2622
2020
Q4
$2.57M Buy
+24,000
New +$2.31M 0.05% 277

Other funds holding ABBV

HRT Financial's ABBV Position: Q1 2026 in Review

HRT Financial opened a new position in AbbVie (ABBV) in Q1 2026: 926,410 shares worth $201M. The stake represents 0.5% of the portfolio and ranks #22 among its holdings. This is a return to the name: HRT Financial previously reported a position in ABBV as recently as Q3 2025.

HRT Financial first reported a position in ABBV in Q4 2014 and has held it in 19 quarters since. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • HRT Financial held 926,410 shares of AbbVie worth $201M as of Q1 2026.
  • AbbVie was a new HRT Financial position in Q1 2026.
  • AbbVie made up 0.5% of HRT Financial's portfolio in Q1 2026, its #22 holding.
  • HRT Financial first reported a position in AbbVie in Q4 2014 and has held it in 19 quarters since.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.